Tony Coles, MD, Former Chairman and CEO of Onyx Pharmaceuticals, Inc., will give the opening keynote at the 19th annual BIO-Europe® international partnering conference in Vienna, Austria, November 4–6, 2013.
Coles’ presentation, “The Onyx Story: Creating a Leading Oncology Company,” is expected to be a big draw at the event just as Amgen and Onyx Pharmaceuticals close their buyout deal valued at USD 10.4 billion. The buyout is the culmination of an impressive run for Onyx with the success of their multiple myeloma drug Kyprolis earlier this year, and the steady revenue influx from Stivarga, a treatment for colorectal cancer and a rare form of gastric cancer. Coles’ leadership in R&D and commercialization strategies at Onyx is considered to be a critical factor in the buyout. Insiders hope the keynote will reveal some of the backstory behind Coles’ genius from his 20-year plus career in the industry, and details about the Amgen acquisition.
Organized by EBD Group in collaboration with the Biotechnology Industry Organization (BIO) and local host Life Science Austria Vienna (LISAvienna), the event is Europe’s largest partnering conference serving the global biotechnology industry.
In addition to the keynote and informative program panels, BIO-Europe is recognized for having high-caliber attendance of senior executives from innovative biotech companies and big pharma who come specifically to participate in one-to-one partnering meetings. Company presentations are also a magnet at BIO-Europe and provide direct access to innovation in the sector. A new track this year is the Academic Innovators™ Showcase in response to pharma’s interest in increased access to academia. The showcase is designed to shine a spotlight on extraordinary scientific advances with strong translational potential, and features presentations from nonprofit universities, institutes and hospitals who are actively conducting preclinical research within a noncommercial setting.
Registration for BIO-Europe is open until November 1 on the BIO-Europe event website, and thereafter on site.
Notes to Editors:
Entry to BIO-Europe 2013 is free to members of the press, including full access to the partnering system, sessions, press conferences, workshops, and pre-arranged partnering meetings. Visit the BIO-Europe conference website atwww.ebdgroup.com/bioeurope/registration/press_reg for registration details.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
The 19th annual BIO-Europe® event will be the largest biotechnology partnering conference held in Europe. Over 3,000 global decision makers from biotechnology, pharma and finance, representing upwards of 1,700 companies from over 50 countries, annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe will take place November 4–6, 2013 in Vienna, Austria.